Health and Healthcare

BioMarin : BMRN

All BioMarin Articles

169 Articles

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Trey Thoelcke | Apr 10, 2014 at 8:00 AM EDT

Who Bucked the Short Interest Trend in Biotech Stocks?

Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back…

Jon C. Ogg | Mar 25, 2014 at 7:55 AM EDT

Top Analyst Upgrades and Downgrades: Arch Coal, BlackBerry, Himax, Palo Alto, Varonis and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, March 25, 2014.…

Trey Thoelcke | Feb 27, 2014 at 7:00 AM EST

Short Sellers Return to Biotech Stocks

After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical…

Trey Thoelcke | Jan 22, 2014 at 9:05 AM EST

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we…

Jon C. Ogg | Jan 14, 2014 at 8:15 AM EST

UBS Has Nine Biotech Buyout and Merger Candidates

The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility…

Jon C. Ogg | Jan 8, 2014 at 8:10 AM EST

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going…

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Lee Jackson | Oct 3, 2013 at 11:50 AM EDT

Top Biotechs Set to Win in the War on Cancer

ThinkstockTuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key…

Jon C. Ogg | Jul 2, 2013 at 8:45 AM EDT

Which Biotech Stocks Are Buyout Targets After Onyx Pharmaceutical Rejects Amgen?

ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for…

Jon C. Ogg | Jun 11, 2013 at 8:10 AM EDT

PropThink Biotech Stocks With Big Upside Potential

ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a U.S. Food and…

Jon C. Ogg | May 7, 2013 at 8:30 AM EDT

Top Wall Street Analyst Upgrades: Arch Coal, Gap, BioMarin and More

Investors and traders seem to be constantly looking for fresh research ideas that will lead to higher income or more…

Jon C. Ogg | May 6, 2013 at 8:10 AM EDT

Top Institutional Portfolio Stocks to Buy at Oppenheimer

ThinkstockFriday’s nonfarm payroll number was a pleasant surprise. However, for real growth to return we need to consistently add 250,000…

Jon C. Ogg | Mar 28, 2013 at 8:50 AM EDT

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

ThinkstockMuch of the research coverage on Wall St. from the bulge bracket firms is concentrated on the most liquid, best…

Jon C. Ogg | Nov 5, 2012 at 9:06 AM EST

BioMarin Drug Meets Endpoint and Will Seek FDA Approval

via Wikimedia CommonsBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is surging on news that a drug met its primary endpoint and that it…

1 … 8 9 10 11 12

BioMarin : BMRN

All BioMarin Articles

UBS Top Stocks to Buy Working for Cancer Cures

Who Bucked the Short Interest Trend in Biotech Stocks?

Top Analyst Upgrades and Downgrades: Arch Coal, BlackBerry, Himax, Palo Alto, Varonis and More

Short Sellers Return to Biotech Stocks

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

UBS Has Nine Biotech Buyout and Merger Candidates

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Top Biotechs Set to Win in the War on Cancer

Which Biotech Stocks Are Buyout Targets After Onyx Pharmaceutical Rejects Amgen?

PropThink Biotech Stocks With Big Upside Potential

Top Wall Street Analyst Upgrades: Arch Coal, Gap, BioMarin and More

Top Institutional Portfolio Stocks to Buy at Oppenheimer

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

BioMarin Drug Meets Endpoint and Will Seek FDA Approval

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

BioMarin : BMRN

All BioMarin Articles

UBS Top Stocks to Buy Working for Cancer Cures

Who Bucked the Short Interest Trend in Biotech Stocks?

Top Analyst Upgrades and Downgrades: Arch Coal, BlackBerry, Himax, Palo Alto, Varonis and More

Short Sellers Return to Biotech Stocks

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

UBS Has Nine Biotech Buyout and Merger Candidates

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Top Biotechs Set to Win in the War on Cancer

Which Biotech Stocks Are Buyout Targets After Onyx Pharmaceutical Rejects Amgen?

PropThink Biotech Stocks With Big Upside Potential

Top Wall Street Analyst Upgrades: Arch Coal, Gap, BioMarin and More

Top Institutional Portfolio Stocks to Buy at Oppenheimer

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

BioMarin Drug Meets Endpoint and Will Seek FDA Approval

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s